Education
About Us
Working with TipRanks
Follow Us
Captor Therapeutics SA (DE:60Q)
STUTTGART:60Q
60Q Stock Chart & Stats
Day’s Range― - ―
52-Week Range€6.96 - €16.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€49.72M
Enterprise Value€137.39M
Total Cash (Recent Filing)€61.42M
Total Debt (Recent Filing)€4.69M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding5,528,709
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.67Price Target Upside-6.37% Downside
Rating ConsensusHold
Number of Analyst Covering1
60Q FAQ
What was Captor Therapeutics SA’s price range in the past 12 months?
Captor Therapeutics SA lowest stock price was €6.96 and its highest was €16.90 in the past 12 months.
What is Captor Therapeutics SA’s market cap?
Captor Therapeutics SA’s market cap is €49.72M.
When is Captor Therapeutics SA’s upcoming earnings report date?
Captor Therapeutics SA’s upcoming earnings report date is Nov 20, 2025 which is in 51 days.
How were Captor Therapeutics SA’s earnings last quarter?
Captor Therapeutics SA released its earnings results on Sep 11, 2025. The company reported -€0.414 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.414.
Is Captor Therapeutics SA overvalued?
According to Wall Street analysts Captor Therapeutics SA’s price is currently Overvalued.
Does Captor Therapeutics SA pay dividends?
Captor Therapeutics SA does not currently pay dividends.
What is Captor Therapeutics SA’s EPS estimate?
Captor Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Captor Therapeutics SA have?
Captor Therapeutics SA has 5,528,709 shares outstanding.
What happened to Captor Therapeutics SA’s price movement after its last earnings report?
Captor Therapeutics SA reported an EPS of -€0.414 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.752%.
Which hedge fund is a major shareholder of Captor Therapeutics SA?
Currently, no hedge funds are holding shares in DE:60Q
Company Description
Captor Therapeutics SA
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
Technical Analysis
Options Prices
Currently, No data available
---